Ventricular Tachycardia Substrate Ablation Versus Antiarrhythmic Drugs: SURVIVE VT

The Substrate Ablation vs Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia (SURVIVE-VT) trial compares the efficacy and safety of catheter ablation versus antiarrhythmic drugs (AAD) as first-line therapy in patients with implantable cardioverter defibrillators (ICD) who present with symptomatic ventricular tachycardias (VT).

0 315 0
More
Worsening Cardiovascular Disease Epidemiology in the United States: The Time for Preparation Is Now

The ongoing COVID-19 pandemic has challenged health care systems worldwide and has brought to the forefront the limitations of providing high-quality health care under system stress.

0 269 0
More
It Is Time to Screen for Heart Failure: Why and How?

There has been significant progress in our ability to identify future risk of development of heart failure (HF).

0 665 0
More
For Best Results in ACS PCI: Treat Upstream With P2Y12 Inhibitors

The Benefit of P2Y12 Inhibitor Pre-treatment

0 652 0
More
Does Subclinical Leaflet Thrombosis Impact the Durability of Bioprosthetic Aortic Valves?

Bioprosthetic aortic valves are increasingly used for surgical aortic valve replacement (SAVR) in patients with aortic stenosis to avoid use of oral anticoagulation therapy (OAC).

0 399 0
More